About Histone-lysine N-methyltransferase SUV39H1
Histone-lysine N-methyltransferase SUV39H1 (SUV39H1) is a protein
from Homo sapiens identified by UniProt accession
O43463, 412 residues long.
MolForge cross-references it against 0 known binders and
144 disease associations.
Target properties
| Protein name | Histone-lysine N-methyltransferase SUV39H1 |
| UniProt accession | O43463 |
| Gene | SUV39H1 |
| Organism | Homo sapiens |
| Length | 412 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (144)
Diseases linked to this target (Open Targets).
- endometrial cancer · score 0.13
- ependymoma · score 0.11
- neoplasm · score 0.11
- acute myeloid leukemia · score 0.10
- breast cancer · score 0.09
- hepatocellular carcinoma · score 0.09
- non-small cell lung carcinoma · score 0.08
- chronic obstructive pulmonary disease · score 0.08
- Systemic lupus erythematosus · score 0.08
- nonpapillary renal cell carcinoma · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O43463-F1 | alphafold | PREDICTED | 88.49 | — |
Amino-acid sequence (412 residues)
MAENLKGCSV CCKSSWNQLQ DLCRLAKLSC PALGISKRNL YDFEVEYLCD YKKIREQEYY LVKWRGYPDS ESTWEPRQNL KCVRILKQFH KDLERELLRR HHRSKTPRHL DPSLANYLVQ KAKQRRALRR WEQELNAKRS HLGRITVENE VDLDGPPRAF VYINEYRVGE GITLNQVAVG CECQDCLWAP TGGCCPGASL HKFAYNDQGQ VRLRAGLPIY ECNSRCRCGY DCPNRVVQKG IRYDLCIFRT DDGRGWGVRT LEKIRKNSFV MEYVGEIITS EEAERRGQIY DRQGATYLFD LDYVEDVYTV DAAYYGNISH FVNHSCDPNL QVYNVFIDNL DERLPRIAFF ATRTIRAGEE LTFDYNMQVD PVDMESTRMD SNFGLAGLPG SPKKRVRIEC KCGTESCRKY LF
Explore Histone-lysine N-methyltransferase SUV39H1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets